The acquisition of Netherlands based ABL broadens our preclinical and clinical offering to include bioanalytical and drug discovery services.
The 60-strong ABL team specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. ABL is active in all phases of drug development, including discovery, pre-clinical and clinical phases.
